From the ¶ Center for Cancer Research, Department of Biology,
Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 and the School of Biological Sciences, Seoul National
University, Seoul, Korea 151-742
Received for publication, December 4, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The CDK9-cyclin T kinase complex, positive
transcription elongation factor b (P-TEFb), stimulates the
process of elongation of RNA polymerase (Pol) II during
transcription of human immunodeficiency virus. P-TEFb associates
with the human immunodeficiency virus Tat protein and with the
transactivation response element to form a specific complex, thereby
mediating efficient elongation. Here, we show that P-TEFb
preferentially phosphorylates hSPT5 as compared with the
carboxyl-terminal domain of RNA Pol II in vitro.
Phosphorylation of hSPT5 by P-TEFb occurred on threonine and serine
residues in its carboxyl-terminal repeat domains. In addition,
we provide several lines of evidence that P-TEFb is a CDK-activating
kinase (CAK)-independent kinase. For example, CDK9 was not
phosphorylated by CAK, whereas CDK2-cyclin A kinase activity was
dramatically enhanced by CAK. Therefore, it is likely that P-TEFb
participates in regulation of elongation by RNA Pol II by
phosphorylation of its substrates, hSPT5 and the CTD of RNA Pol II, in
a CAK-independent manner.
Efficient transcription of full-length proviral DNA of human
immunodeficiency virus (HIV)1
is controlled by the viral protein Tat. Tat is expressed early in the
viral life cycle and is essential for viral replication and gene
expression (1-3). Tat recognizes the bulge region of TAR
(transactivation response element), an RNA stem-loop structure located
at the 5' end of HIV transcripts (4, 5). Although the precise molecular
mechanism by which Tat exerts its transcriptional activation is not
completely understood, it has been suggested that Tat stimulates
transcription by RNA polymerase (Pol) II predominately at the level of
elongation rather than initiation (6, 7).
Recent studies indicate that P-TEFb (positive transcription elongation
factor b) is a key cellular factor supporting Tat-dependent elongation (8-12). P-TEFb, originally identified from Drosophila melanogaster, was purified as a suppressor of an inhibitor of elongation by RNA Pol II (8, 9) and is composed of kinase subunit CDK9
and its cyclin partner cyclin T (11-15). P-TEFb efficiently phosphorylates the CTD of RNA Pol II and in fact is associated with
elongating RNA Pol II in vitro (16-18). The kinase activity of P-TEFb is sensitive to DRB, an inhibitor of elongation by RNA Pol II. Furthermore, Tat binds specifically to human P-TEFb via a
cyclin T subunit (13, 14, 19). A specific cysteine residue, 261 of human cyclin T, is critical for the interaction of Tat with P-TEFb,
and rodent cells that encode a cyclin T lacking this cysteine residue
are defective for Tat activation (13, 14, 19-23). Finally, depletion
of P-TEF from HeLa nuclear extract decreased not only basal
transcription but also Tat-dependent transcription elongation (11, 24).
In addition to P-TEFb, Tat-dependent activation of
transcription is also regulated by other cellular factors including
TAT-SF1 and DSIF (hSPT4 and 5). TAT-SF1 was identified using a
partially purified reconstituted reaction that supports
Tat-dependent TAR-specific stimulation of elongation (25,
26). TAT-SF1, a phosphoprotein, contains two RNA recognition motifs and
a highly acidic domain at its carboxyl terminus (26). TAT-SF1 binds to
Tat, and its overexpression can stimulate Tat-dependent
activation in vivo (26, 27). In addition, TAT-SF1 forms a
protein complex including TFIIF (RAP30), P-TEFb, hSPT5, and RNA Pol II
that is thought to mediate Tat-dependent activation
in vitro (27-30).
DSIF (hSPT4 and 5) was originally isolated as a factor that renders
transcription in vitro inhibitable by DRB (35). DSIF forms a protein complex with the negative elongation factor to inhibit
promoter proximal elongation by RNA Pol II (31-34). Release from this
inhibition is mediated by P-TEFb, specifically through phosphorylation
by its DRB-sensitive kinase CDK9 (32, 34). DSIF is also important for
Tat activation, because nuclear extracts depleted of hSPT5 do not
support Tat-dependent elongation in vitro (27,
29, 30). Additionally, overexpression of hSPT5 stimulates Tat-specific
activation in vivo (27). In yeast, SPT5 increases the
efficiency of elongation of RNA Pol II complexes (35).
Several studies have also implicated TFIIH in Tat activation
(36-39). TFIIH is a general transcription factor that forms a preinitiation complex with RNA Pol II (40-43). TFIIH is composed of
nine polypeptides (p34, p44, p54, p62, CDK7, cyclin H, MAT1, ERCC2, and
ERCC3). TFIIH is not only essential for RNA Pol
II-dependent transcription but is also important for DNA
repair and cell cycle regulation (41, 42). An important component of
TFIIH is the CDK7 subunit, which interacts with cyclin H and MAT1 to
form CAK (CDK-activating kinase) and phosphorylates the CTD of RNA Pol II (41-44). Recent genetic and biochemical evidence strongly suggests that this phosphorylation of the CTD is important for interaction of
the CTD with capping enzymes that modify the nascent transcript (45-47). Surprisingly, these results also showed that the
phosphorylation state of the CTD is significantly altered as the
polymerase continues to elongate. The CAK, CDK7-cyclin H, is also known
to specifically phosphorylate a threonine residue in the T-loop of
other CDKs (48, 49). This phosphorylation stimulates the activity of these CDK kinases.
In this study, we have shown that P-TEFb prefers hSPT5 as a substrate
as compared with the CTD of RNA Pol II. Unlike other CDKs, CDK9 is not
phosphorylated by CAK but undergoes autophosphorylation. These results
suggest that P-TEFb mediates RNA Pol II CTD phosphorylation independent
of CAK activity during stimulation of elongation.
In Vitro Kinase Assay--
Kinase assays were performed as
described previously (9, 11). Briefly, 20 µl of kinase reaction
contained 20 mM HEPES (pH 7.5), 10 mM
MgCl2, 0.1 mg/ml bovine serum albumin, 10 µM
ATP, 5 µCi of [ Preparation of Recombinant Proteins--
Plasmid
pBAK-HuCDK9-T1 was kindly provided by D. Price. Recombinant
CDK9-cyclin T protein complex was expressed in Hi5 cells by use
of baculovirus and was prepared as described previously (11, 14). The
full length of CDK9WT (wild type) cDNA was amplified by
polymerase chain reaction. CDK9TA and CDK9DN mutant cDNAs were produced by polymerase chain reaction with the following
oligonucleotides (only the sense strand):
5'GTCCTGAAGCTGGCAAACTTTGGGCTGGCCCGG3' for CDK9D167N
and 5'CAGCCCAACCGCTACGCCAACCGTGTGGTGACA3' for CDKT186A (mutation sites are indicated with underlines). These CDK9 cDNAs were again polymerase chain reaction-cloned to fuse in frame into the
pFAST-BacHTa vector (Life Technologies, Inc.). Hi5 cells were infected
with baculovirus containing these CDK9 cDNAs with histidine tags at the
amino terminus. Recombinant CDK9 proteins were purified as recommended
by the manufacturer (Life Technologies, Inc.). For expression of
various recombinant hSPT5 proteins, the following plasmids were
polymerase chain reaction-cloned from wild type hSPT5 cDNA and fused in
frame into the EcoRI and SalI sites of pET28+a
(Novagen): FL (full-length), which contains amino acids (aa) 1-1087 of
hSPT5; the amino-terminal domain, which contains aa 1-271 of hSPT5;
the middle domain, which contains aa 272-756 of hSPT5; the
carboxyl-terminal domain, which contains aa 757-1087 of hSPT5;
CTR (C-terminal repeat), which contains aa 757-920 of hSPT5. To prepare histidine-tagged hSPT5 proteins, these DNA constructs were transformed into Escherichia coli BL21(DE3), and
proteins were induced and purified by affinity chromatography with a
nickel-conjugated agarose column as recommended by the
manufacturer (Novagen). Recombinant TAT-SF1 protein was prepared as
described previously (27). Purified CAK (CDK7-cylin H) and CDK2-cyclin
A proteins were kindly provided by N. P. Pavletich.
Western Blots--
Western blots were performed as described
previously (27). Briefly, recombinant proteins were resolved by
SDS-polyacrylamide gel electrophoresis and then transferred to a
polyvinylidene difluoride membrane. The blots were incubated with each
antibody and visualized using an ECL kit (Amersham Pharmacia Biotech).
Antibodies against CDK9 and the histidine tag were purchased from Santa
Cruz Biotechnology and used at a dilution of 1:1000.
Phosphoamino Acid Analysis and Phosphopeptide
Mapping--
Phosphorylated hSPT5 proteins were prepared by incubation
in a P-TEFb kinase assay as described above. Phosphorylated peptides were resolved in a 4-20% SDS-polyacrylamide gel electrophoresis and
then transferred to polyvinylidene difluoride membrane. With phosphopeptides eluted from the membrane, phosphoamino acid analysis and phosphopeptide mapping were performed as described (50, 51), except
that plastic cellulose TLC plates (EM Science) and a Multiphor II
electrophoretic system were used (Amersham Pharmacia Biotech).
P-TEFb Phosphorylates hSPT5 and the CTD of RNA Pol II--
DRB
inhibits transcription at the stage of elongation in vivo
(52, 53). During transcription in vitro, DRB also
selectively inhibits elongation as compared with initiation, probably
by suppressing kinase activities such as those responsible for CTD
hyperphosphorylation (54, 55). Among many CTD kinases, CAK and P-TEFb
have relatively well characterized functions in RNA Pol II
transcription in vitro. Both kinases are DRB-sensitive (10,
11, 38, 39). As part of the characterization of P-TEFb, the DRB
sensitivity of both kinases was examined using baculovirus-expressed
P-TEFb (CDK9-cyclin T) and CAK (CDK7-cyclin H). When GST·CTD
was used as substrate, the IC50 of DRB was estimated as 2.5 and 20 µM for P-TEFb and CAK, respectively (Fig.
1A). This result suggests that
P-TEFb is significantly more sensitive to inhibition by DRB than CAK, which is consistent with previous results (9-11). This observation is
also consistent with the inhibition of P-TEFb controlling the DRB-sensitive elongation process both in vivo and in
vitro. Approximately 2-5 µM DRB yields a 50%
decrease in transcription activity (10, 11).
To date, the CTD of RNA Pol II is the best known substrate of P-TEFb.
To test whether P-TEFb can phosphorylate other molecules involved in
Pol II-dependent transcription, P-TEFb kinase assays were
performed with several other substrates: hSPT5, CAK, CDK2-cyclin A,
TAT-SF1, and histone H1. GST·CTD was included as a positive control.
As shown in Fig. 1B, P-TEFb phosphorylated both GST·CTD and hSPT5 more efficiently than the other proteins tested. In fact,
P-TEFb phosphorylated hSPT5 more effectively than GST·CTD at the same
substrate concentration (Fig. 1B). We therefore further investigated the enzyme-substrate specificity of P-TEFb. Both hSPT5 and
GST·CTD proteins were serially diluted to measure the Km value for P-TEFb (Fig. 1C). The
calculated values for hSPT5 and GST·CTD were 18 and 55 nM, respectively. Moreover, because the GST·CTD contains
52 YSPTPSP repeats, each of which is a potential site of
phosphorylation, whereas hSPT5 probably contains fewer potential sites,
these Km values probably underestimate the
preference of hSPT5 as a substrate.
P-TEFb Phosphorylates the Carboxyl Terminus of
hSPT5--
To determine the preferential phosphorylation domains
of hSPT5 by P-TEFb, hSPT5 was divided into the following three domains: the amino-terminal domain, which is rich in acidic amino acid; the
middle domain, which contains KOW motifs similar to those of E. coli NusG proteins; and the carboxyl-terminal domain, which contains CTR heptapeptide repeats (Fig.
2A) (33). Each of the recombinant hSPT5 proteins was histidine-tagged and expressed in
E. coli (Fig. 2B). As shown in Fig.
2C, P-TEFb efficiently phosphorylated the carboxyl-terminal
domain of hSPT5 rather than the amino-terminal or middle domains,
although a low level of phosphorylation of the middle domain was
detected. The CTR domain contains multiple serine and threonine
residues that could be potential phosphorylation sites by the
serine/threonine kinase P-TEFb. To test which amino acids of hSPT5 are
phosphorylated by P-TEFb, phosphoamino acid analysis was performed. As
shown in Fig. 2D, 75 and 25% of hSPT5 phosphorylations
occurred at the threonine and serine residues, respectively, whereas
tyrosine phosphorylation was not observed. To confirm that the CTR is
the major phosphorylation domain of hSPT5 by P-TEFb, two-dimensional phosphopeptide mapping was performed with recombinant FL and CTR proteins. FL and CTR phosphopeptides produced by digestion with trypsin
were resolved on TLC plates. Most of the separated phosphopeptides of
the CTR proteins comigrated with those of the FL protein,
suggesting that the high affinity phosphorylation sites of hSPT5 are in
the CTR domain.
Phosphorylation of Threonine 186 of CDK9 and Kinase
Activity--
The kinase activities of CDKs can be regulated by
several mechanisms. The binding of a cyclin partner is one of the
activation processes. Some CDKs are activated by phosphorylation of a
specific threonine residue in their T-loop. CAK (CDK7-cyclin H) is
responsible for phosphorylation in the T-loop of several CDKs including
CDK2, 4, and 6 (48, 49). CDK9 shows 39% identity with CDK2, the best
characterized kinase whose activity is controlled by CAK. More
importantly, CDK9 has a threonine residue at position 186 in the T-loop
region that is conserved in the corresponding region of CDK2. Two
different point mutants of CDK9 were made to study the functional role
of phosphorylation of this site (Fig.
3A). First, threonine 186 of
CDK9 was mutated to alanine (CDK9TA), which does not undergo
phosphorylation. Second, aspartic acid 167 of CDK9 was mutated to
asparagine (CDK9DN), which abrogates its kinase activity. Although
catalytically inactive, the latter mutant protein probably folds
into a native conformation because it functions as a dominant negative
in vivo (10). These CDK9 mutants were expressed in insect
cells by use of the baculovirus system and purified. The kinase
activity of CDK9 was enhanced 4-5-fold when bound by cyclin T (Fig.
3B, lanes 1, 2, 5, and
6). As expected, CDK9DN had no kinase activity, whereas
CDK9TA had approximately the same activity as CDK9WT. (Note that in
Fig. 3C a lower amount of CDK9TA than CDK9WT was used in the
reactions shown in lanes 3 and 7.) In addition,
phosphorylation of CDK9 was detected in CDK9WT and CDK9-cyclin T assays
(Fig. 3C, lanes 1, 2, 5,
and 6), but it was not detected when CDK9TA was tested. This
shows that 1) the CDK9 kinase can undergo autophosphorylation and 2) the primary site of autophosphorylation of CDK9 under these conditions is at Thr-186. In addition, these data indicate that the
kinase activity of CDK9 is not strongly dependent upon phosphorylation of the threonine residue in its T-loop.
CDK9 Kinase Activity and Phosphorylation--
Although threonine
186 of CDK9 is dispensable for its kinase activity, it is important to
determine whether this conserved threonine of CDK9 could be a substrate
for phosphorylation by CAK, which could modulate its kinase activity.
Two different approaches were used to test the possibility that CAK
could phosphorylate and thus activate CDK9-cyclin T. First, CDK9WT and
mutants including CDK9TA and CDK9DN were tested as substrates
for CAK. As shown in Fig.
4A, phosphorylation of CDK9WT
but not CDK9TA or CDK9DN was observed in the presence of CAK
(CDK7-cyclin H). The lack of phosphorylation of CDK9DN or CDK9TA was
not due to the loss of CAK activity because CAK could actively
phosphorylate histone H1 (Fig. 4A, lane 2).
Therefore, threonine 186 of CDK9 is apparently not a substrate site of
CAK, because CDK9DN, which contains this threonine, was not
phosphorylated by CAK. Second, the CDK9-cyclin T complex was tested as
a substrate instead of a CDK9 monomer in a CAK assay because
the associated cyclin might induce a structural change in the T-loop.
In parallel, CDK2-cyclin A was used as a positive control for the CAK
assay. Confirming previous results, CDK2-cyclin A has
negligible ability to autophosphorylate, whereas the level of
phosphorylation of CDK2-cyclin A was increased about 68-fold in the
presence of CAK (Fig. 4, B and C). Unlike
CDK2-cyclin A, phosphorylation of the CDK9 subunit of the CDK9-cyclin T
complex was not increased by CAK. (Fig. 4, B and
C). These observations strongly suggest that CDK9 is not
phosphorylated by CAK at either threonine 186 or any other residue(s).
The phosphorylation of CDK9 appears to be due to its autokinase
activity.
We also tested whether P-TEFb kinase activity might be cooperatively
regulated by CAK. In this case, P-TEFb kinase activities were examined
using two substrates, hSPT5 and GST·CTD, in the absence or presence
of CAK. As shown in Fig. 5, A
and B, CDK2-cyclin A kinase activity was greatly enhanced by
CAK (105-fold or more), whereas the P-TEFb kinase activity for either
substrate hSPT5 or GST·CTD was barely changed by CAK. When different
CDK substrates (GST·CTD (a common substrate of P-TEFb, CAK,
and CDK2-cyclin A) and hSPT5 (a P-TEFb-specific substrate))
were compared, each of these kinase combinations showed a similar
pattern of substrate phosphorylation. We conclude that the CDK9 kinase
activity of P-TEFb is independent of CAK.
Phosphorylation of CDK9 and Kinase Activity--
CDK9 is
autophosphorylated on Thr-186 in the T-loop. To test whether this
autophosphorylation further activated the kinase, CDK9 was preincubated
with ATP to form phosphorylated CDK9. Then the kinase activities of
CDK9 with or without preincubation were compared. As shown in Fig.
6, the degree of phosphorylation of CDK9
was increased in an ATP preincubation-dependent manner
(Fig. 6A, lanes 2, 4, 6,
and 8). However, the phosphorylation of hSPT5 was not
increased by preincubation of CDK9 (Fig. 6, A and
B). This observation is consistent with Fig. 3, which showed
that CDK9TA had kinase activity. Thus, these data suggest that the phosphorylation of CDK9 is not a critical post-translational
modification needed for kinase activity.
The results presented indicate that P-TEFb, composed of CDK9 and
cyclin T, preferentially phosphorylates hSPT5 as compared with the CTD
of RNA Pol II in vitro. Furthermore, the CDK9 kinase is not
regulated by CAK even though it contains a conserved threonine common
to many CAK-activated CDKs. These results suggest that P-TEFb in a
CAK-independent manner could activate Tat-dependent elongation by phosphorylating hSPT5 as well as the CTD of RNA Pol II.
The CDK7 kinase of TFIIH probably has at least two distinct functions
in cells. Several studies indicate that CDK7 regulates RNA Pol II
activity by phosphorylation of its CTD. In addition, because CDK7
phosphorylates the conserved threonine of CDK2 and other CDKs, it is
also thought to be a regulator of the cell cycle machinery (48). A
functional role for CDK7 in Tat-stimulated elongation is still
controversial. Several studies with CAK inhibitors support the idea
that CDK7-cyclin H is also important for Tat activation (38, 39).
However, there is accumulating evidence that P-TEFb is the major kinase
involved in Tat-activated transcription (12, 16). Recently, the
physical association of elongating RNA Pol II with P-TEFb, but not with
CAK, provided strong evidence for the primacy of P-TEFb in
Tat-dependent elongation (17).
We have tested whether CAK phosphorylation of the CDK9 component of
P-TEFb would modulate the activity of this kinase. This does not appear
to be the case, because CDK9 phosphorylation did not increase by
incubation with CAK, and the kinase activity of CDK9 was not enhanced
by CAK. The finding that a catalytically inactive mutant of CKD9, which
is defective for autophosphorylation, was not detectably phosphorylated
by CAK is the most direct evidence for the former. CDK9
autophosphorylation was observed with the WT kinase and was inactivated
by mutation of threonine 186 to alanine. This change did not alter the
kinase activity of P-TEFb for either CTD or SPT5. The observation that
the threonine 186 to alanine mutant protein is not autophosphorylated
appears to conflict with results reporting that CDK9 will
autophosphorylate its carboxyl terminus and that this modification is
important for binding to TAR (57, 58). The explanation may be
that the reactions in this study contained lower concentrations of the CDK9 kinase and were incubated for much briefer periods of time than
the previous work. We tested whether CAK-partially phosphorylated CTD
of RNA Pol II was a preferred substrate for P-TEFb. However, this was
not the case, because phosphorylation of GST·CTD by P-TEFb alone was
not significantly different from P-TEFb plus CAK. Taken together, it is
likely that CAK and P-TEFb work in an independent manner in RNA Pol
II-dependent transcription.
The kinase activity of P-TEFb is important for CTD phosphorylation of
RNA Pol II, which correlates with efficient elongation (9, 11). DSIF,
composed of hSPT4 and hSPT5, was originally purified on the basis of
rendering transcription in vitro dependent upon P-TEFb and
thus inhibitable by DRB (31-33). Furthermore, a newly identified
negative elongation factor complex works in conjunction with DSIF to
stall elongation of RNA Pol II shortly after initiation (34). Extensive
studies by Handa and coworkers (32-34) suggest that P-TEFb
stimulates RNA Pol II elongation from this position by CTD
phosphorylation. Thus, the kinase activity of P-TEFb alleviates the
repression activity of DSIF at an early stage of elongation (32).
Many studies have also shown that P-TEFb is critical for HIV-1
Tat-activated transcription elongation (12). For example, the
sensitivity to inhibition by the drug DRB and other compounds of Tat
activation of transcription in vivo corresponds to the sensitivity of the kinase activity of P-TEFb but not of other known CDKs (10). DSIF is also important for Tat activation of elongation, as shown by depleting reactions in vitro of this
complex. Other evidence that Spt5 functions in a positive mode in
elongation is the phenotype of mutations in this gene in yeast. Loss of
function mutants can have a decreased efficiency of elongation
(35).
Phosphorylation of SPT5 by P-TEFb could be important in Tat activation
of elongation. This kinase preferentially phosphorylates the repetitive
carboxyl domain of SPT5, which is necessary to observe Tat activation
in vitro (56). The opposing roles of SPT5 in elongation,
inhibition, and stimulation could reflect roles in two processes. In
the promoter proximal process, SPT4 and 5 (DSIF) stalls polymerase
elongation, which is relieved by phosphorylation by P-TEFb
probably of the CTD of Pol II (32). This process has been well
documented in vitro for many promoters. A second process,
which for HIV is Tat-mediated and dependent upon TAR, probably forms
after polymerase has elongated beyond the TAR element. This process
would depend upon P-TEFb, bound to TAR in the presence of Tat,
interacting with SPT5, probably by phosphorylation, to stimulate
elongation over long segments of the template. The existence of two
P-TEFb-dependent processes would be consistent with the
results of Fong and Zhou (58) and would explain why cyclin T from
sources other than humans can function in general transcription from
the HIV promoter, but only human cyclin T can function in
Tat-dependent stimulation of transcription (14). Finally,
recent evidence showing that SPT5 and SPT6 are associated with
elongating polymerase, whereas SPT4 and SPT5 (as DSIF) are adequate for
promoter proximal events, further supports two roles for SPT5 (59,
60).
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP, 50-100 ng of substrates,
and 10 ng of purified kinases. The reactions were incubated at 30 °C
for 5 min. Protein complexes were resolved by SDS-polyacrylamide gel
electrophoresis. The gels were dried and exposed to x-ray film.
Reaction products were quantified by using a PhosphorImager and
the ImageQuant program (Molecular Dynamics).
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (38K):
[in a new window]
Fig. 1.
DRB sensitivity of P-TEFb kinase and
identification of P-TEFb substrates. A, DRB
sensitivities of P-TEFb (CDK9-cyclin T) and CDK7-cyclin H kinase
complexes were examined with GST·CTD as substrate. 10 ng of P-TEFb or
CDK7-cyclin H complex were used to phosphorylate GST·CTD (100 ng)
with indicated amounts of DRB. B, in vitro P-TEFb
kinase assay with various substrates. Recombinant P-TEFb (CDK9-cyclin
T) complex was mixed with indicated proteins (50 ng) during the
in vitro kinase assay. Positions of heavily phosphorylated
GST·CTD and SPT5 are marked with arrowheads. Positions of
TAT-SF1, cyclin T, CDK9, and histone H1 are marked with
arrows on the right. C, titration of
recombinant hSPT5 and GST·CTD proteins during the in vitro
P-TEFb kinase assay. Indicated amounts of substrates of either hSPT5 or
GST·CTD were used with 20 ng of P-TEFb. To get a similar intensity,
the film of phosphorylated GST·CTD was exposed two times longer than
that of phosphorylated SPT5.
View larger version (58K):
[in a new window]
Fig. 2.
Analysis of hSPT5 phosphorylation by P-TEFb
kinase. A, schematic of recombinant hSPT5 proteins. The
amino-terminal domain contains aa 1-271 of the hSPT5 protein; the
middle domain contains aa 272-756 of the hSPT5 protein; the
carboxyl-terminal domain contains aa 757-1087 of the hSPT5 protein;
and CTR contains aa 757-920 of the hSPT5 protein. NT,
amino-terminal domain; MD, middle domain; CT,
carboxyl-terminal domain. B, immunoblotting
(IB) of recombinant hSPT5 proteins with anti-His antibody.
30-50 ng of histidine-tagged recombinant hSPT5 proteins were resolved
via a 4-20% SDS-polyacrylamide gel electrophoresis and
immunoblotted with anti-His antibody. C, in vitro
P-TEFb (CDK9-cyclin T) assay with various hSPT5 recombinant proteins.
10 ng of P-TEFb kinase were mixed with indicated hSPT5 proteins during
the in vitro kinase assay. Positions of phosphorylated CDK9
and cyclin T are marked with arrowheads. D,
phosphoamino acid analysis of wild type hSPT5. Phosphorylated
full-length hSPT5 proteins were obtained by an in vitro
kinase assay with P-TEFb and then analyzed by phosphoamino acid
analysis. Positions of phosphoserine (P-S), phosphothreonine
(P-T), and free phosphate (Pi) are
marked. E, two-dimensional phosphopeptide mapping.
Recombinant FL and CTR of hSPT5 proteins were phosphorylated by P-TEFb
as in C. Phosphorylated proteins were digested with trypsin
(20 units), eluted, and then loaded for TLC.
View larger version (35K):
[in a new window]
Fig. 3.
Kinase activity assay with CDK9 wild type and
mutant proteins. A, mutation position of CDK9 D N and
CDK9 T
A (see details under "Experimental Procedures").
B, in vitro kinase assay with CDK9-cyclin T,
CDK9WT, CDK9DN, and CDK9TA proteins. 100 ng of GST·CTD (lanes
1-4) and 25 ng of recombinant hSTP5 (lanes 5-8)
proteins were used as substrates. C, immunoblotting
(IB) of recombinant CDK9 proteins with anti-CDK9
antibody. The same amounts of CDK9 proteins (10 ng) were used for both
the in vitro kinase assay (B) and immunoblotting
(C).
View larger version (23K):
[in a new window]
Fig. 4.
CAK assay with CDK9
proteins as substrate. A, in vitro
CDK7-cyclin H kinase assay with various CDK9 proteins and histone H1.
20 ng of CDK9 proteins and 100 ng of histone H1 proteins were used in
the CAK assay. Positions of phosphorylated CDK7, CDK9, and
histone H1 are indicated with arrows. B, 50 ng of
CDK9-cyclin T complex and 50 ng of CDK2-cyclin A complex were incubated
in the absence or presence of CAK (20 ng) assay. C,
quantitation of phosphorylated CDK2, CDK7, and CDK9 proteins from
B as determined using a PhosphorImager.
View larger version (34K):
[in a new window]
Fig. 5.
Effect of CAK on P-TEFb kinase activity.
A, the kinase activity of CDK9-cyclin T and CDK2-cyclin A
complexes was examined in the absence or presence of CAK (CDK7-cyclin
H). Recombinant hSPT5 (lanes 2 and 3) and
GST·CTD (lanes 5 and 6) proteins were used for
the CDK9-cyclin T kinase assay. For CDK2-cyclin A kinase, GST·CTD was
used (lanes 7 and 8). CAK (CDK7-cyclin H) was
incubated with the CDK9-cyclin T complex (lanes 3 and
6) and CDK2-cyclin A (lane 8). Positions of
phosphorylated hSPT5, GST·CTD, CDK9, and CDK7 are marked.
B, quantitation of phosphorylated hSPT5 and GST·CTD from
A.
View larger version (43K):
[in a new window]
Fig. 6.
Effects of phosphorylation of CDK9 on P-TEFb
kinase activity. A, CDK9WT or the CDK9-cyclin T complex
was preincubated with cold ATP (10 µM) for 5 min at
30 °C (lanes 2, 4, 6, and
8). Then recombinant hSPT5 protein (25 ng) was added to
kinase reactions (lanes 3, 4, 7, and
8). Positions of phosphorylated hSPT5 and CDK9 are indicated
with an arrowhead and arrows, respectively.
B, quantitation of phosphorylated CDK9 protein or hSPT5
protein from A.
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]() |
ACKNOWLEDGEMENTS |
---|
We thank K. B. Lee, D. Dykxhoorn, D. Tantin, and V. Wang for valuable advice and helpful comments. We also thank M. Siafaca for assistance with the preparation of the manuscript.
![]() |
FOOTNOTES |
---|
* This work was supported by United States Public Health Service Grants RO1-AI32486 and PO1-CA42063 from the National Institutes of Health and partially by NCI, National Institutes of Health, Cancer Center Support (core) Grant P30-CA14051.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ A Special Fellow of The Leukemia & Lymphoma Society and currently supported by a BK21 Research Fellowship from the Ministry of Education and Human Resources Development and SNU Research Fund.
To whom correspondence should be addressed. Tel.:
617-253-6421; Fax: 617-253-3867; E-mail: sharppa@mit.edu.
Published, JBC Papers in Press, January 5, 2001, DOI 10.1074/jbc.M010908200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are:
HIV, human
immunodeficiency virus;
TAR, transactivation response element;
Pol, polymerase;
P-TEFb, positive transcription elongation factor b;
CDK, cyclin-dependent kinase;
CTD, carboxyl-terminal domain;
CAK, CDK-activating kinase;
aa, amino acids;
GST, glutathione
S-transferase;
FL, full-length;
DRB, 5,6-dichloro--D-ribofuranosylbenzimidazole;
WT, wild
type;
CTR, carboxyl-terminal repeat.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Cullen, B. R. (1993) Cell 93, 685-692 |
2. |
Emerman, M.,
and Malim, M. H.
(1998)
Science
280,
1880-1884 |
3. |
Jones, K. A.
(1997)
Genes Dev.
11,
2593-2599 |
4. | Feng, S., and Holland, E. C. (1988) Nature 334, 165-167[CrossRef][Medline] [Order article via Infotrieve] |
5. | Ratnasabapathy, R., Sheldon, M., Johal, L., and Hernandez, N. (1990) Genes Dev. 4, 2061-2074[Abstract] |
6. | Marciniak, R. A., Calnan, B. J., Frankel, A. D., and Sharp, P. A. (1990) Cell 63, 791-802[Medline] [Order article via Infotrieve] |
7. | Marciniak, R. A., and Sharp, P. A. (1991) EMBO J. 10, 4189-4196[Abstract] |
8. |
Marshall, N. F.,
Peng, J.,
Xie, Z.,
and Price, D. H.
(1996)
J. Biol. Chem.
271,
27176-27183 |
9. |
Marshall, N. F.,
and Price, D. H.
(1995)
J. Biol. Chem.
270,
12335-12338 |
10. |
Mancebo, H. S.,
Lee, G.,
Flygare, J.,
Tomassini, J.,
Luu, P.,
Zhu, Y.,
Peng, J.,
Blau, C.,
Hazuda, D.,
Price, D.,
and Flores, O.
(1997)
Genes Dev.
11,
2633-2644 |
11. |
Zhu, Y.,
Pe'ery, T.,
Peng, J.,
Ramanathan, Y.,
Marshall, N.,
Marshall, T.,
Amendt, B.,
Mathews, M. B.,
and Price, D. H.
(1997)
Genes Dev.
11,
2622-2632 |
12. |
Price, D. H.
(2000)
Mol. Cell. Biol.
20,
2629-2634 |
13. | Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., and Jones, K. A. (1998) Cell 92, 451-462[Medline] [Order article via Infotrieve] |
14. |
Peng, J.,
Zhu, Y.,
Milton, J. T.,
and Price, D. H.
(1998)
Genes Dev.
12,
755-762 |
15. |
Peng, J.,
Marshall, N. F.,
and Price, D. H.
(1998)
J. Biol. Chem.
273,
13855-13860 |
16. |
Chen, D.,
and Zhou, Q.
(1999)
Mol. Cell. Biol.
19,
2863-2871 |
17. |
Ping, Y. H.,
and Rana, T. M.
(1999)
J. Biol. Chem.
274,
7399-7404 |
18. | Isel, C., and Karn, J. (1999) J. Mol. Biol. 290, 929-941[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Garber, M. E.,
Wei, P.,
KewalRamani, V. N.,
Mayall, T. P.,
Hermann, C. H.,
Rice, A. P.,
Littman, D. R.,
and Jones, K. A.
(1998)
Genes Dev.
12,
3512-3527 |
20. |
Bieniasz, P. D.,
Grdina, T. A.,
Bogerd, H. P.,
and Cullen, B. R.
(1998)
EMBO J.
17,
7056-7065 |
21. |
Fujinaga, K.,
Taube, R.,
Wimmer, J.,
Cujec, T. P.,
and Peterlin, B. M.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
1285-1290 |
22. |
Chen, D.,
Fong, Y.,
and Zhou, Q.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2728-2733 |
23. | Kwak, Y. T., Ivanov, D., Guo, J., Nee, E., and Gaynor, R. B. (1999) J. Mol. Biol. 288, 57-69[CrossRef][Medline] [Order article via Infotrieve] |
24. |
Zhou, Q.,
Chen, D.,
Pierstorff, E.,
and Luo, K.
(1998)
EMBO J.
17,
3681-3691 |
25. | Zhou, Q., and Sharp, P. A. (1995) EMBO J. 14, 321-328[Abstract] |
26. |
Zhou, Q.,
and Sharp, P. A.
(1996)
Science
274,
605-610 |
27. |
Kim, J. B.,
Yamaguchi, Y.,
Wada, T.,
Handa, H.,
and Sharp, P. A.
(1999)
Mol. Cell. Biol.
19,
5960-5968 |
28. |
Li, X. Y.,
and Green, M. R.
(1998)
Genes Dev.
12,
2992-2996 |
29. | Wu-Baer, F., Lane, W. S., and Gaynor, R. B. (1998) J. Mol. Biol. 277, 179-197[CrossRef][Medline] [Order article via Infotrieve] |
30. |
Parada, C. A.,
and Roeder, R. G.
(1999)
EMBO J.
18,
3688-3701 |
31. |
Wada, T.,
Takagi, T.,
Yamaguchi, Y.,
Ferdous, A.,
Imai, T.,
Hirose, S.,
Sugimoto, S.,
Yano, K.,
Hartzog, G. A.,
Winston, F.,
Buratowski, S.,
and Handa, H.
(1998)
Genes Dev.
12,
343-356 |
32. |
Wada, T.,
Takagi, T.,
Yamaguchi, Y.,
Watanabe, D.,
and Handa, H.
(1998)
EMBO J.
17,
7395-7403 |
33. |
Yamaguchi, Y.,
Wada, T.,
Watanabe, D.,
Takagi, T.,
Hasegawa, J.,
and Handa, H.
(1999)
J. Biol. Chem.
274,
8085-8092 |
34. | Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J., and Handa, H. (1999) Cell 97, 41-51[Medline] [Order article via Infotrieve] |
35. |
Hartzog, G. A.,
Wada, T.,
Handa, H.,
and Winston, F.
(1998)
Genes Dev.
12,
357-369 |
36. |
Garcia-Martinez, L. F.,
Mavankal, G.,
Neveu, J. M.,
Lane, W. S.,
Ivanov, D.,
and Gaynor, R. B.
(1997)
EMBO J.
16,
2836-2850 |
37. | Parada, C. A., and Roeder, R. G. (1996) Nature 384, 375-378[CrossRef][Medline] [Order article via Infotrieve] |
38. |
Yankulov, K.,
Yamashita, K.,
Roy, R.,
Egly, J. M.,
and Bently, D. L.
(1995)
J. Biol. Chem.
270,
23922-23925 |
39. |
Cujec, T. P.,
Okamoto, H.,
Fujinaga, K.,
Meyer, J.,
Chamberlin, H.,
Morgan, D. O.,
and Peterlin, B. M.
(1997)
Genes Dev.
11,
2645-2657 |
40. |
Holstege, F. C. P.,
and Young, R. A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2-4 |
41. | Svejstrup, J. Q., Vichi, P., and Egly, J. M. (1996) Trends Biochem. Sci. 20, 346-350[CrossRef] |
42. | Hoeijmakers, J. H. J., Egly, J. M., and Vermeulen, W. (1996) Curr. Opin. Genet. Dev. 6, 26-33[Medline] [Order article via Infotrieve] |
43. |
Hampsey, M.
(1998)
Microbiol. Mol. Biol. Rev.
62,
465-503 |
44. | Tirode, F., Busso, D., Coin, F., and Egly, J.-M. (1999) Mol. Cell 3, 87-95[Medline] [Order article via Infotrieve] |
45. |
Cho, E. J.,
Takagi, T.,
Moore, C. R.,
and Buratowski, S.
(1997)
Genes Dev.
11,
3319-3326 |
46. |
Rodriguez, C. R.,
Cho, E. J.,
Keogh, M. C.,
Moore, C. L.,
Greenleaf, A. L.,
and Buratowski, S.
(2000)
Mol. Cell. Biol.
20,
104-112 |
47. |
Hirose, Y.,
and Manley, J. L.
(2000)
Genes Dev.
14,
1415-1429 |
48. | Morgan, D. O. (1995) Nature 374, 131-134[CrossRef][Medline] [Order article via Infotrieve] |
49. | Dynlacht, B. D. (1997) Nature 389, 149-152[CrossRef][Medline] [Order article via Infotrieve] |
50. | Kamps, M. P., and Sefton, B. M. (1989) Anal. Biochem. 176, 22-27[Medline] [Order article via Infotrieve] |
51. | van der Geer, P., and Hunter, T. (1994) Electrophoresis 15, 544-554[Medline] [Order article via Infotrieve] |
52. | Sehgal, P. B., Darnell, J. E., and Tamm, I. (1976) Cell 9, 473-480[Medline] [Order article via Infotrieve] |
53. | Tamm, I., Hand, R., and Caliguiri, L. A. (1976) J. Cell Biol. 69, 229-240[Abstract] |
54. | Egyhazi, E. (1974) J. Mol. Biol. 84, 173-183[Medline] [Order article via Infotrieve] |
55. |
Chodosh, L. A.,
Fire, A.,
Samuels, M.,
and Sharp, P. A.
(1989)
J. Biol. Chem.
264,
2250-2257 |
56. |
Ivanov, D.,
Kwak, Y. T.,
Guo, J.,
and Gaynor, R. B.
(2000)
Mol. Cell. Biol.
20,
2970-2983 |
57. |
Garber, M. E.,
Mayall, T. P.,
Suess, E. M.,
Meisenhelder, J.,
Thompson, N. E.,
and Jones, K. A.
(2000)
Mol. Cell Biol.
20,
6958-6969 |
58. |
Fong, Y. W.,
and Zhou, Q.
(2000)
Mol. Cell. Biol.
20,
5879-5907 |
59. |
Kaplan, C. D.,
Morris, J. R.,
Wu, C.-t.,
and Winston, F.
(2000)
Genes Dev.
14,
2623-2634 |
60. |
Andrulis, E. D.,
Guzman, E.,
Doring, P.,
Werner, J.,
and Lis, J. T.
(2000)
Genes Dev.
14,
2635-2649 |